Empiric IV therapy for suspected bacterial meningitis in adults 18–50 without immunocompromise?

• A. Ceftriaxone alone
• B. Ampicillin plus gentamicin
• C. Vancomycin plus ceftriaxone
• D. Vancomycin alone

Answer: (C)

In adults 18–50 without immunocompromise, empiric meningitis therapy aims to cover the two most common and potentially resistant organisms: Neisseria meningitidis and Streptococcus pneumoniae. A third-generation cephalosporin like ceftriaxone covers N. meningitidis and many strains of S. pneumoniae, while adding vancomycin provides protection against penicillin-resistant pneumococcus. Listeria monocytogenes becomes a concern mainly in patients over 50 or those with immunocompromise, so ampicillin is not routinely added in this age group. Vancomycin alone wouldn’t address Neisseria or many gram-negative pathogens, and ceftriaxone alone wouldn’t reliably cover penicillin-resistant pneumococcus. Gentamicin has limited CSF penetration and is not ideal for empiric meningitis therapy. Therefore, the best empiric regimen is vancomycin plus ceftriaxone to ensure broad coverage against the common pathogens and resistant strains while awaiting culture results.